HLS Therapeutics (TSE:HLS) Stock Price Down 0.3% – Should You Sell?

HLS Therapeutics Inc. (TSE:HLS) shares fell 0.3% during trading on Friday . The company traded as low as C$3.33 and last traded at C$3.64. 59,500 shares changed hands during trading, an increase of 111% from the average session volume of 28,252 shares. The stock had previously closed at C$3.65.

Wall Street Analyst Weigh In

Separately, Raymond James increased their price objective on HLS Therapeutics from C$4.00 to C$5.00 in a research note on Friday, November 22nd.

HLS Therapeutics Trading Down 0.3 %

The business has a fifty day moving average price of C$3.55 and a 200 day moving average price of C$3.44. The company has a market capitalization of C$115.72 million, a PE ratio of -3.60 and a beta of 1.07. The company has a debt-to-equity ratio of 100.44, a quick ratio of 1.01 and a current ratio of 2.02.

About HLS Therapeutics

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.